LATEST PODCAST:  Escape the Scale-Up Trap - Redefining Manufacturing Strategies    Listen now!

4 min read

AGC Biologics Welcomes Multiple Cell Therapy Projects to New Yokohama Site

AGC Biologics Welcomes Multiple Cell Therapy Projects to New Yokohama Site

Developers ranging from academic institutions to biotechnology companies select AGC Biologics for its proven commercial track record

Showcases momentum for Japan’s cell and gene therapy ecosystem following proactive government initiatives

YOKOHAMA, Japan, November 17, 2026 — While there is growing interest and momentum for cell and gene therapy development in Japan, there are a limited number of CDMOs with the institutional knowledge, manufacturing prowess, talent development, and international network. To advance their projects in a fast-paced, resource-constrained environment, three biopharma developers including the Institute of Science Tokyo have selected AGC Biologics to provide cell therapy services from its new Yokohama location.

AGC established its cell therapy services in Yokohama in July 2025, bringing together two strong legacies: thirty years of expertise and the track record of the AGC Biologics Milan site, and AGC Group’s century-plus manufacturing excellence in Japan. Combined, those legacies position AGC to meet the burgeoning needs of the cell and gene therapy industry.

As part of these new projects, the AGC Biologics Yokohama site will provide services such as process transfer and manufacturing services for pre-clinical and clinical trials. Core technologies available for developers with diverse needs include induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, exosomes, and CAR-T cell therapies.

Supporting Clinical Translation of Virus-Specific T Cell Therapy Research

Among the projects the Yokohama site will support is a research program led by the Institute of Science Tokyo aimed at advancing third-party virus-specific T cell therapy for treatment-resistant adenovirus infections following hematopoietic cell transplantation toward clinical application.

“Viral infections following hematopoietic cell transplantation represent a major clinical challenge in patients with compromised immune function and can lead to severe, potentially life-threatening complications," said Takahiro Kamiya, M.D., Ph.D., Junior Associate Professor at the Institute of Science Tokyo Graduate School of Medical and Dental Sciences. “With support from the Japanese Agency for Medical Research and Development under its Research Program for Intractable Diseases, we are advancing the research and development of virus-specific T-cell therapy toward clinical implementation for refractory adenovirus infections following hematopoietic cell transplantation.”

At the Yokohama site, AGC Biologics supports this program through process development and analytical method development activities intended to facilitate future clinical and manufacturing implementation.

Coordination with the AGC Biologics Milan Cell and Gene Center of Excellence

One of the new projects involves the transfer of a customer program from the Milan site to the Yokohama site, where AGC will conduct future development and manufacturing activities. Through coordination across its global network, AGC Biologics provides flexible development and manufacturing support tailored to customers' evolving needs and business environments.

“By combining technologies developed across our global network with AGC's unique materials expertise, we provide globally aligned development support services to customers worldwide,” said Tadashi Murano, President of AGC Life Science Company. “Going forward, we will continue to provide integrated support from early-stage development through commercialization, helping accelerate our customers' research and development activities.”

“AGC Biologics has accumulated extensive experience in the development and manufacturing of cell therapy products through its global operations,” said Takahiro. “As we prepare for this collaboration, we have also been impressed by the strength of its research and development capabilities, its robust infrastructure, and the dedication and enthusiasm of its team.”

Development and manufacturing provided by the AGC Biologics Cell and Gene Technologies Division has led to 18 commercial approvals for its customers and their products.

Improved landscape for cell and gene therapy development in Japan

As outlined in a recent analysis by Dark Horse Consulting and AGC Biologics, proactive government action and regulatory changes have brought a new wave of early-stage development and attention to cell and gene therapy development in Japan.

“As Western biopharmaceuticals and investors increasingly turn their attention eastward, much of the spotlight has centered on China, driven by its scale, clinical speed and cost advantages,” according to H. Deborah Chen and Kang Liu, the authors of the new report, From Laboratory to Launchpad: Japan's Cell and Gene Therapy Ecosystem Hits Its Stride. “Yet, Japan with its deep scientific expertise, expanding manufacturing infrastructure, and strong global accessibility represents both a growing market and a potential hub for CGT innovation across Asia that should not be overlooked.”

The full report outlines why Japan presents a compelling opportunity for global CGT developers, as well as some key considerations for developers aiming to build a presence or conduct trials in Japan.

 

 Frequently Asked Questions (FAQs):